WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsSTAAR Surgical Company (STAA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 11774% more annual revenue ($28.43B vs $239.44M). MDLN leads profitability with a 4.1% profit margin vs -33.6%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

STAA

Hold

42

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 6.7Quality: 8.0
Piotroski: 2/9Altman Z: 2.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.03

$24.89 discount

UndervaluedFair: $66.92Overvalued

Intrinsic value data unavailable for STAA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN0 strengths · Avg: 0/10

No standout strengths identified

STAA4 strengths · Avg: 8.3/10
Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.768/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
18.1%8/10

18.1% revenue growth

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

STAA4 concerns · Avg: 2.5/10
Market CapQuality
$867.46M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-21.7%2/10

ROE of -21.7% — below average capital efficiency

EPS GrowthGrowth
-10.5%2/10

Earnings declined 10.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : STAA

The strongest argument for STAA centers on Debt/Equity, PEG Ratio, Price/Book. Revenue growth of 18.1% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : STAA

The primary concerns for STAA are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

MDLN profiles as a value stock while STAA is a growth play — different risk/reward profiles.

STAA is growing revenue faster at 18.1% — sustainability is the question.

STAA generates stronger free cash flow (-2M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 42/100) and 14.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

STAAR Surgical Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.

Visit Website →

Want to dig deeper into these stocks?